By Isabel Demetz
(Reuters) -World’s largest dialysis specialist Fresenius Medical Care reported first-quarter results above market expectations on Tuesday, as revenue grew organically in all its segments.
The German company’s revenue was 4.88 billion euros ($5.53 billion) in the quarter, slightly above analysts’ average estimate of 4.85 billion in a poll compiled by Vara Research. That was up from 4.73 billion euros in the same period in 2024.
Operating income adjusted for special items grew to 457 million euros from 403 million euros last year, beating analysts’ expectations of 446 million euros.
While patient treatment in the U.S. took a hit from missed appointments in February due to high numbers of flu and cold cases, analysts were expecting those numbers to improve through March and April.
FMC, which made 67% of its quarterly revenue through dialysis procedures in the United States, said payments from medical insurers and favourable U.S. dollar to euro exchange rate offset the decrease in dialysis days.
The dialysis provider for 300,000 patients worldwide confirmed its guidance for 2025 and continues to expect market treatment growth in the U.S. to be more than 0.5% this year.
($1 = 0.8831 euros)
(Reporting by Isabel Demetz in Gdansk, editing by Milla Nissi-Prussak)
